Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis Clinical Trial
Official title:
A Phase Ⅲb, Multicenter, Double-blind, Randomized, Controlled Trial, to Assess the Efficacy and Safety of Indacaterol (150㎍ o.d.) vs. Placebo, in Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis
This clinical study will assess efficacy and safety of indacaterol (150㎍ o.d.) in patients with Chronic Obstructive Pulmonary Disease (COPD) with destroyed lung by tuberculosis.
There are few clinical studies in patients with COPD with destroyed lung by tuberculosis
because tuberculosis patients are usually excluded from (phase II or III) clinical trials
for drug registration although they are not prohibited from prescription of COPD drugs.
This clinical study will assess efficacy and safety of indacaterol (150㎍ o.d.) in patients
with COPD with destroyed lung by tuberculosis.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment